Synthesis of a potent aminopyridine-based nnos-inhibitor by two recent no-carrier-added 18f-labelling methods

Article abstract of DOI:10.3390/molecules21091160

Nitric oxide (NO), an important multifunctional signaling molecule, is produced by three isoforms of NO-synthase (NOS) and has been associated with neurodegenerative disorders. Selective inhibitors of the subtypes iNOS (inducible) or nNOS (neuronal) are of great interest for decoding neurodestructive key factors, and 18F-labelled analogues would allow investigating the NOS-function by molecular imaging with positron emission tomography. Especially, the highly selective nNOS inhibitor 6-((3-((3-fluorophenethylamino)methyl)phenoxy)methyl)-4-methylpyridin-2-amine (10) lends itself as suitable compound to be 18F-labelled in no-carrier-added (n.c.a.) form. For preparation of the 18F-labelled nNOS-Inhibitor [18 F]10 a "build-up" radiosynthesis was developed based on a corresponding iodonium ylide as labelling precursor. The such activated phenethyl group of the compound was efficiently and regioselectively labelled with n.c.a. [18 F]fluoride in 79% radiochemical yield (RCY). After conversion by reductive amination and microwave assisted displacement of the protecting groups, the desired nNOS-inhibitor was obtained in about 15% total RCY. Alternatively,for a simplified "late-stage" 18F-labelling procedure a corresponding boronic ester precursor was synthesized and successfully used in a newer, copper(II) mediated n.c.a. 18F-fluoro-deboroniation reaction, achieving the same total RCY. Thus, both methods proved comparatively suited to provide the highly selective NOS-inhibitor [18 F]10 as probe for preclinical in vivo studies.

Full text of DOI:10.3390/molecules21091160

molecules
Article
Synthesis of a Potent Aminopyridine-Based
nNOS-Inhibitor by Two Recent No-Carrier-Added
18F-Labelling Methods
Christian Drerup, Johannes Ermert * and Heinz H. Coenen
Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich, 52425 Jülich,
Germany; ch.drerup@fz-juelich.de (C.D.); h.h.coenen@fz-juelich.de (H.H.C.)
* Correspondence: j.ermert@fz-juelich.de; Tel.: +49-2461-61-3110
Academic Editor: Michael Gütschow
Received: 3 August 2016; Accepted: 25 August 2016; Published: 1 September 2016
Abstract: Nitric oxide (NO), an important multifunctional signaling molecule, is produced by three
isoforms of NO-synthase (NOS) and has been associated with neurodegenerative disorders. Selective
inhibitors of the subtypes iNOS (inducible) or nNOS (neuronal) are of great interest for decoding
neurodestructive key factors, and 18F-labelled analogues would allow investigating the NOS-function
by molecular imaging with positron emission tomography. Especially, the highly selective nNOS
inhibitor 6-((3-((3-fluorophenethylamino)methyl)phenoxy)methyl)-4-methylpyridin-2-amine (10
)
lends itself as suitable compound to be 18F-labelled in no-carrier-added (n.c.a.) form. For preparation
of the 18F-labelled nNOS-Inhibitor [18F]10 a “build-up” radiosynthesis was developed based on a
corresponding iodonium ylide as labelling precursor. The such activated phenethyl group of the
compound was efficiently and regioselectively labelled with n.c.a. [18F]fluoride in 79% radiochemical
yield (RCY). After conversion by reductive amination and microwave assisted displacement of the
protecting groups, the desired nNOS-inhibitor was obtained in about 15% total RCY. Alternatively,
for a simplified “late-stage” 18F-labelling procedure a corresponding boronic ester precursor was
synthesized and successfully used in a newer, copper(II) mediated n.c.a. 18F-fluoro-deboroniation
reaction, achieving the same total RCY. Thus, both methods proved comparatively suited to provide
the highly selective NOS-inhibitor [18F]10 as probe for preclinical in vivo studies.
Keywords: radiofluorination; radiopharmaceuticals; nNOS-inhibitor; iodonium ylides; copper-mediated
labelling
1. Introduction
Nitric oxide (NO) is an important signalling molecule and a unique mediator of a variety of
physiological and pathological processes in the human body [
1]. NO is synthesized endogenously
from L-arginine by the enzyme nitric oxide synthase (NOS) existing in three isoforms [
2]. There are
two low-output isoforms of the NOS family, producing NO constitutively: the neuronal (nNOS) and
the endothelial (eNOS) isoform. The nNOS generates NO as a neurotransmitter in brain and peripheral
nerve cells, whereas eNOS derived NO is involved in the regulation of blood pressure, primarily
in vascular endothelial cells. In contrast, the third, inducible (iNOS) isoform is induced by various
inflammatory stimuli (e.g., endotoxin) and plays a crucial role in the immune system’s defence against
pathogens and tumour cells. Once expressed, the iNOS can generate high amounts of NO up to
concentrations and for a prolonged period of time such as for hours or days [3].
µM
Various studies have shown that dysregulation of iNOS derived NO is closely implicated
in numerous acute and chronic inflammatory diseases, e.g., septic shock [ ], asthma [ ] and
multiple sclerosis [ ]. In addition, iNOS activity has also been found in many tumours [ 11].
4
5
6
–
9
9–
Molecules 2016, 21, 1160; doi:10.3390/molecules21091160
www.mdpi.com/journal/molecules

Molecules 2016, 21, 1160
2 of 21
Equally important, earlier studies have revealed that overproduction of NO by the nNOS is
associated with neurodegenerative diseases, including Parkinson’s [12], Alzheimer’s [13] and
Huntington’s diseases [14], multiple sclerosis [15], headaches [16] and neuronal damage in stroke [17].
Thus, assessing the in vivo activity of iNOS or nNOS would provide insight into a multitude of
physiologic and pathologic processes. Therefore, isoform-selective NOS imaging using suitable
positron emitting inhibitors and non-invasive positron emission tomography (PET) would particularly
be desirable and probably be of tremendous value for the study and treatment of NO related diseases.
Given the central role of nNOS in a variety of diseases, PET may provide new avenues for diagnostics,
the clinical management of affected patients, and it may facilitate the drug discovery and development
process for new therapies that target NOS activity.
Because of the central role of iNOS and nNOS in NO related diseases, numerous efforts
have been made to develop effective inhibitors as pharmaceuticals. This ranges from nonselective
L-arginine analogues [18] to selective inhibitors reported recently [19
interfere with eNOS, to ensure proper functioning of the cardiovascular system [19
and co-workers developed different aminopyridine-based molecules conceived as inhibitors for
targeting the neuronal NOS [22 24]. In this context 6-(((3R,4R)-4-(2-((3-fluorophenethyl)amino)
ethoxy)pyrrolidin-3-yl)methyl)-4-methylpyridin-2-amine ( , Figure 1) shows high potency with a
Ki value of 7 nM for nNOS and very high selectivity over iNOS (806-fold) and eNOS (2667-fold) [23].
,20], that do especially not
,
21]. Silverman
–
1
Figure 1. Novel NOS inhibitors: 6-(((3R,4R)-4-(2-((3-fluorophenethyl)amino)ethoxy)pyrrolidin-3-yl)
methyl)-4-methylpyridin-2-amine ( ) [23] and 6-((3-(((3-fluorophenethyl)amino)methyl)phenoxy)methyl)-
4-methylpyridin-2-amine (10) [25].
1
In addition to a high potency and excellent isozyme-selectivity, the blood-brain-barrier
permeability is a major challenge in the development of nNOS inhibitors. The same authors speculated
that the therapeutic utility of 1 is limited by poor membrane permeability due to the two secondary
amino groups [25]. Therefore, different strategies were applied to lower the possibility of forming
positive charges at physiological pH at these positions and to improve the bioavailability [24].
Replacing the pyrrolidine group of
1 with a benzyl group lowered not only proton acceptor
characteristics, but reduced also the number of chiral centres and enabled an easier synthesis. Especially
the derivative 6-((3-((3-fluorophenethylamino)methyl)phenoxy)methyl)-4-methylpyridin-2-amine
(10, Figure 1) combined comparable high potency and selectivity for nNOS (Ki = 40 nM;
147-fold selectivity over iNOS and 261-fold over eNOS) [25] with a high probability to penetrate
the blood-brain-barrier, thus satisfying the requirements for its application as a potential
nNOS-radio inhibitor.
The aim of this study was to develop a synthesis for the preparation of the 18F-labelled inhibitor
[18F]10 as potential molecular imaging probe for the pathophysiologically interesting nNOS-isozyme
and for further pharmacological and preclinical studies in order to localize, identify and quantify
neurodestructive processes.
2. Results and Discussion
2.1. Synthesis of Reference Compounds and Precursors for a “Build-Up” Labelling Procedure
Previous work on the synthesis of potential inhibitors of neuronal nitric oxide synthase with
rather simple structures provide a suitable preparative way for the reference compound 10 which is

Molecules 2016, 21, 1160
3 of 21
needed for an unambiguous identification of the desired radiolabelled nNOS-tracer. The following
synthesis concept was used (see Scheme 1). After pyrrole-protection of 2-amino-4,6-dimethylpyridine
2
and deprotonation of
according to an earlier report [26]. The resulting compound
starting material for coupling with 3-hydroxybenzaldehyde in compliance with the literature [25].
4, the lithiated compound 5 was quenched with trimethylsilylchloride (TMSCl),
6
was bromodesilylated, yielding
7
as
Scheme 1. Synthesis of the aldehyde 8 as building block for the synthesis of the reference compound
10 and th◦e precursor 19. Reagents and conditions: (a) p-TsOH, toluene, reflux, 48 h; (b) n-BuLi, THF,
◦
◦
2 h,
−
78 C to 0 C; (c) TMSCl, THF, 1 h, 0 C; (d) BrF2CCF2Br, CsF, DMF, 3 h, room temperature;
◦
(e) 3-hydroxybenzaldehyde, K2CO3, acetone, 4 h, 60 C; steps a–d, see [26]; step e, see [25].
The pyrrole protected reference compound
9
was obtained after reductive amination of
8
with 3-fluorophenethylamine. Using methanol as protic solvent instead of the recommended
1,2-dichloroethane [25], increased the yield from 64% to 89%, as shown in Scheme 2, due to complete
reduction of the imine intermediate. After deprotection of the amino group with NH2OH HCl,
·
according to the literature [25], the nNOS inhibitor 10 was obtained and used as reference compound
for further High performance liquid chromatography (HPLC) measurements.
Scheme 2. Preparation of the nNOS inhibitor 10 as reference compound. Reagents and conditions:
(a) NaBH(OAc)3, 3-fluorophenethyl amine, MeOH, 3 h, room temperature; (b) NH2OH
EtOH/H2O (2:1), 20 h, 100 C; step (b), see [25].
·
HCl,
◦
Different approaches were considered for the radiosynthesis of the desired nNOS tracer [18F]10
.
The first concept was planned as a multistep radiosynthesis based on the use of an iodonium ylide
as precursor for labelling. Former studies have shown that aryliodonium ylides are a promising
alternative to the well-known diaryliodonium salts for the direct preparation of complex, electron
rich no-carrier-added (n.c.a.) [18F]fluoroarenes [27
,28]. However, recent findings about the reaction
of ylides had to be considered. Especially, an unexpected formation of regioisomers as reported by
Cardinale et al. [28] was a hint to additionally investigate the influence of the substitution pattern on
the radiochemical yield during n.c.a. 18F-radiofluorination of iodonium ylide precursors. Therefore,
the positional isomers 14o and 14p were synthesized in addition to the required iodonium ylide 14m
which was needed as precursor for the conversion to the desired nNOS inhibitor 10.
Starting from 3-iodophenylacetonitrile 11 the corresponding primary amine 12 was obtained by
reduction with borane. It was Boc-protected and subsequently converted with m-CPBA, potassium
hydroxide and Meldrum’s acid to the corresponding iodonium ylide precursor 14m in analogy to the
literature [29] as shown in Scheme 3. The purification of the crude product was performed by column
chromatography yielding 43% of the meta-substituted iodonium ylide precursor 14m.

Molecules 2016, 21, 1160
4 of 21
Scheme 3. Synthesis of the iodonium ylide precursor 14m. Reagents and conditions: (a) 1. BH3
·
THF,
70 ◦C, 2 h; 2. EtOH, HCl Et2O, 0 ◦C, 5 min; (b) Boc2O, NaHCO3, MeOH, 50 ◦C, ultrasound, 30 min;
·
(c) 1. m-CPBA, DCM, RT, 2 h; 2. KOH, Meldrum’s acid, room temperature, 15 min; 3. combined mixture
of 1. and 2. (analogous to [29]).
The corresponding fluorophenethylcarbamates 15o, 15m and 15p (13 with a fluorine in place of an
iodine atom) were synthesized as reference compounds for radio-HPLC-identification, starting from
commercially available fluorophenethylamines and were obtained in high yields of about 96%–98%.
2.2. 18F-Radiosynthesis of the nNOS-Inhibitor 10 via the “Build-Up” Procedure
As mentioned, Cardinale et al. observed the formation of two regioisomers during the preparation
of the receptor ligand 4-((4-[18F]fluorophenoxy)phenylmethyl)piperidine with the corresponding
para-substituted iodonium ylide precursor [28]. For a “build-up” synthesis of desired nNOS-tracer,
however, the radiofluorinated intermediate [18F]15m must be synthesised in high radiochemical yield
and high purity, avoiding any radioactive side product. Thus, for a careful examination of the n.c.a.
radiofluorination of the iodonium ylide precursor 14m as starting material for “build-up” of [18F]9
,
◦
the ortho- and para-substituted ylides 14o and 14p were also labelled with n.c.a. [18F]fluoride at 110 C
in DMF with Kryptofix®2.2.2 (K222) and potassium carbonate ([18F]KF/K222), according to general
procedures [28].
Comparing the generated products, the cine-substitution was not observed with any isomer of
14 under the reaction conditions chosen here. Therefore, the reaction conditions could be applied
which were used for 18F-labelling of the three isomers of anisole ylide [28]. The required precursors
were synthesised according to the same literature [28] and purified using column chromatography as
proven successful.
The radiofluorination of the examined iodonium ylides showed a high regioselectivity in all cases.
In contrast to literature the formation of isomers was not observed. The yields of 18F-fluorinated
products after systematic labelling of all isomers are shown in Figure 2. Furthermore, different
radiochemical yields for the labelling of the three carbamate isomers are clearly depicted. The trend
observed for radiochemical yield (RCY) (meta > para > ortho) depends on substitution pattern,
mesomeric and inductive effects, but obviously also on a steric effect, considering the ortho-derivative.
Figure 2 also shows the relation between the amount of precursor 14m used and the resulting
radiochemical yield. A reduction of the mass of precursor to 12.5
µmol caused a decrease of the
resulting RCY, while an increase to 37.5 mol only modestly augmented the RCY and on account of
µ
a simultaneous enlargement of the standard deviation. An amount of 25
accordance with more constant product yields.
µmol seemed preferable in
A high yield of the labelled intermediate [18F]15m is to be achieved from 14m for the “build-up”
synthesis of the nNOS-tracer. Therefore, the dependence of the RCY of [18F]15m on reaction time
and temperature was examined in detail (see Figure 3). Highest yields were obtained after 10 min at
temperatures between 110 ◦C and 150 ◦C. At temperatures between 130 ◦C and 150 ◦C, however, a
RCY of up to 73% was obtained already after a reaction time of 5 min.
For the following “build-up” synthesis an amount of precursor of 25
µmol and a reaction time of
10 min at 110 ◦C was chosen due to the comparably small standard deviations observed there.

Molecules 2016, 21, 1160
5 of 21
Figure 2. Effect of the amount of precursor on radiochemical yield (RCY) of different phenethylcarbamates
and anisoles in dependence of the substitution pattern.
Figure 3. Influence of reaction temperature and time of the nucleophilic radiofluorination of ylide 14m
,
yielding [18F]15m. For reagents and conditions see Scheme 4, step a.
O
O
N
H
O
O
N
H
O
NH2
a
b
I
18F
18F
[
18F]21
O
O
O
14m
[
18F]15m
18F
18F
c
d
O
O
N
N
N
H2N
N
N
H
H
[
18F]9
[
18F]10
Scheme 4. “Build-up” radiosynthesis of the nNOS-inhibitor
[
18F]10
.
Reagents and conditions:
(a) Kryptofix®2.2.2, K2CO3, no-carrier-added (n.c.a.) [18F]fluoride, DMF, 110 ◦C, 10 min; (b) HCl
◦
in dioxane, 15 min, 80 C; (c)
8
, NaBH(OAc)3, room temperature, 15 min; (d) NH2OH
·
HCl, EtOH, H2O,
◦
max. 50 W microwave irradiation, 100 C, 10 min.

Molecules 2016, 21, 1160
6 of 21
The successful radiosynthesis of synthon [18F]15m provided a good basis for the following
“build-up” synthesis of the nNOS-inhibitor. The intermediate [18F]15m was trapped after
radiofluorination on a reversed-phase resin for removal of ionic components formed. 65%–80% of
total radioactivity was retained on the column used in the 18F-fluorination process, whereas unreacted
[18F]fluoride was most likely eluted as waste. After elution with dioxane and deprotection, the
resulting amine [18F]21 was converted by reductive amination in presence of the aldehyde
8 and
sodium triacetoxyborohydride to the pyrrole protected nNOS-inhibitor [18F]9 as shown in Scheme 4.
The reductive amination yielded compound [18F]9 in a rather variable RCY of 6%–40% (n = 4).
The subsequent deprotection was carried out under microwave heating. This four-step “build-up”
process yielded the desired nNOS-inhibitor [18F]10 in a maximum radiochemical yield of 15%.
The procedure was not further optimized due to a highly promising “late-stage” 18F-labelling method
examined in parallel.
2.3. Synthesis of Reference Compound and Precursor for a “Late-Stage” 18F-Labelling Procedure
The recently introduced “late-stage” approach for nucleophilic n.c.a. 18F-labelling, based on a
boronic acid pinacol ester as precursor, seemed attractive for application to the radiofluorination of the
desired nNOS tracer. Especially, the new copper-mediated method for labelling organic boronic acid
esters with n.c.a. [18F]fluoride as published in 2014 by Tredwell et al. [30] found ample application
in drug development and got into the focus of radiochemistry. The radiofluorination of electron-rich
arenes, generally not amenable to aromatic nucleophilic substitution (SNAr) with [18F]fluoride, can
thereby be performed through reaction of pinacol-derived aryl boronic esters with [18F]KF/K222
in the presence of [Cu(OTf)2(py)4] (OTf = trifluoromethanesulfonate, py = pyridine). This method
was meanwhile adapted to various aromatic systems, as it tolerates a variety of different functional
groups [30,31]. Therefore, it is of high interest, and it appeared potentially useful as alternative for
labelling of the desired nNOS inhibitor.
For the preparation of a corresponding boronic acid pinacol ester precursor the appropriate
iodinated derivative 18 of the nNOS-inhibitor was synthesized as starting material. This was achieved
by reductive amination of aldehyde 8 with 3-iodophenethylamine 12 (see Scheme 5).
Scheme 5. Synthesis of the boronic acid pinacol ester, precursor 19. Reagents and conditions:
(a) NaBH(OAc)3, MeOH, 3 h, room temperature; (b) Boc2O, DMAP, MeOH, 15 min, room temperature;
0
(c) bis-pinacolatodiborane, potassium acetate, [1,1 -bis(diphenylphosphino)ferrocene]dichloropalladium(II),
◦
DMF, 85 C, 90 min.
For the cross-coupling as well as for the radiosynthesis, the secondary amine 17 was Boc-protected
in high yield of about 87%. The pyrrole- and Boc-protected iodide 18 was converted by a palladium
catalysed cross-coupling reaction to the pinacol ester 19 in ca. 64% yield. For the work-up process

Molecules 2016, 21, 1160
7 of 21
of 19 the iodide 18 had to be fully converted, otherwise the product could not be separated from the
starting material. Therefore, an extensive work-up procedure, including preparative reversed-phase
column chromatography, was needed, since normal-phase chromatography led to decomposition of
19. The Boc-protected 19F-reference compound 20 was synthesized to unambiguously identify the
radiolabelled product, starting from 9 in about 83% RCY (see Scheme 6).
Scheme 6. Synthesis of the reference compound of intermediate 20. Reagents and conditions: (a) Boc2O,
DMAP, MeOH, 15 min, room temperature.
2.4. Radiosynthesis of the nNOS-Inhibitor [18F]10 by “Late-Stage” Nucleophilic 18F-Labelling
The preparation of the nNOS-inhibitor [18F]10 started with the 18F-fluorination of the boronic
ester (ArylBPin) 19 in the presence of n.c.a. [18F]fluoride and the copper(II)-complex [Cu(OTf)2(py)4]
for mediation of the [18F]fluorine-aryl bond formation. In accordance to literature [31] it was found,
that a conventional labelling protocol, using macroscopic amounts of [18F]KF/K222 in acetonitrile, is
not applicable for this copper-mediated labelling method. The original labelling protocol [30] also
indicates that only comparatively low amounts of potassium carbonate and Kryptofix®2.2.2 will allow
product formation.
With regard to a prospective automation, a one-pot procedure for the preparation of the
nNOS-inhibitor was developed. Drying and activating of the [18F]fluoride ion with potassium
carbonate and Kryptofix®2.2.2 as well as copper mediated labelling should ideally be performed
in one reaction vessel. A diminution of the amounts of potassium carbonate and Kryptofix®2.2.2 is
desirable, but also limited due to a decreasing efficiency of [18F]fluoride release using QMA cartridges.
Hence, a minimum amount of anions is necessary for an efficient release of [18F]fluoride from QMA
cartridge after fixation.
The best results were observed with 46 mg QMA-cartridges from Waters® (Milford, MA, USA) and
an elution mixture consisting of 2.6 µmol of tetraethylammonium bicarbonate (TEAHCO3) in 0.8 mL
of methanol as a compromise between efficient [18F]fluoride release from the resin and moderate
18F-labelling yields. Under these conditions the loss of [18F]fluoride during fixation and release,
which was carried out in the same flow direction, did not exceed 15%.
In accordance to the literature and along with the proposed reaction mechanism of the copper
mediated fluorination [32], it was found that the ventilation of the Wheaton® (Millville, NJ, USA)
vial with air after the drying process has a positive effect on the RCY. After the drying procedure the
precursor was converted in presence of the copper-complex to [18F]20 (see Scheme 7). The influence
of the reaction temperature and time on this radiofluorination was also examined in more detail.
Previous studies on the copper-mediated reaction of [18F]fluoride with pinacol boronic esters indicated
that the use of DMF as solvent and a temperature of 110 ◦C gave high RCYs [30,31].
◦
Figure 4 shows that the highest yields were obtained after 10 min reaction time at 120 C;
however, standard deviations are comparatively high. More reproducible results were achieved
after 15 min at 110 ◦C. Higher temperatures and longer reaction times led to the formation of polar,
radioactive by-products. These unidentified products though, never exceeded 5% of the total activity.
Reaction times longer than 15 min seem only relevant if low temperatures are necessary with given
sensible precursors.

Molecules 2016, 21, 1160
8 of 21
Scheme 7. “Late-stage” 18F-labelling of the nNOS-inhibitor
[
18F]10
HCl, EtOH, H2O, max. 50 W
.
Reagents and conditions:
(a) TEAHCO3, n.c.a. [18F]fluoride, DMF, 110 ◦C, 15 min; (b) NH2OH
·
◦
microwave irradiation, 100 C, 10 min.
Figure 4. Influence of reaction temperature and time on copper-mediated radiofluorination of
precursor 19. All syntheses were carried out manually and RCY was determined by radio thin layer
chromatography (TLC). Each experiment was carried out at least in triplicate. Reagents and conditions:
30 µL MeCN, 10 mg (15 µmol) 19, 3.5 mg (5 µmol) CuIIOTf2py4 in 300 µL DMF.
The 18F-fluorinated product [18F]20 was trapped on a reversed-phase cartridge and eluted for
deprotection of the pyrrole and the Boc-group into a special microwave vessel. After microwave
treatment in the presence of NH2OH
The radiochemical yield of the desired nNOS-tracer [18F]10 based on the starting activity was about
14%
5% (n = 4). Even with the small amounts of n.c.a. [18F]fluoride (30–100 MBq) used for
the developmental work performed here, high molar activities of 48 GBq/ mol were achieved.
·
HCl the product was easily isolated by solid phase extraction.
±
≥
µ
Batch production of 18F-labelled ligands with higher starting activity, carried out with the same
technological equipment in our institute, however, resulted reliably in even higher molar activities
of ≥90 GBq/µmol [33].
3. Materials and Methods
3.1. General Information
All chemicals were purchased from Sigma-Aldrich GmbH (Steinheim, Germany), Fluka (Buchs,
Switzerland), Merck KGaA (Darmstadt, Germany), ChemPUR GmbH (Karlsruhe, Germany) or
Activate Scientific (Prien, Germany) and used without further purification. All reactions were carried
out by standard air-free and moisture-free techniques under an inert atmosphere of argon. Dry solvents
were purchased in sufficient purity.

Molecules 2016, 21, 1160
9 of 21
Thin layer chromatography (TLC) was done on precoated plates ALUGRAM® SIL G/UV254
(Macherey-Nagel GmbH, Düren, Germany) or on TLC silica gel 60 RP-18 F254 (Merck KGaA), and the
compounds were detected at 254 nm. Flash column chromatography was conducted manually on silica
S
gel 60 (35–70
µ
m) from Merck KGaA or by using the Reveleris
™
flash chromatography system from
Grace (Worms, Germany) with evaporative light scattering (ELS) and UV detection. H-, 11B-, 13C- and
19F-Nuclear Magnetic Resonance (NMR) spectra were recorded at ZEA (Forschungszentrum Jülich)
on a Bruker DPX Avance 200 spectrometer (Bruker, Billerica, MA, USA), a Varian Inova 400 MHz
1
(Varian Inc., Palo Alto, CA, USA) or on a Bruker Avance 600. All shifts are given below in
δ (ppm)
using the signals of the corresponding solvent as reference. All coupling constants (J) are given in
Hz. Splitting patterns are typically described as follows: s: singlet, d: doublet, t: triplet, m: multiplet.
Mass spectra were obtained with a Finnigan Automass Multi mass spectrometer with an electron beam
energy of 70 eV. High-resolution mass spectrometry (HRMS) spectra were recorded on a FTICR “LTQ
FT Ultra” (both from Thermo Fisher Scientific, Braunschweig, Germany). Elemental analyses (EA,
microanalyses) were carried out at ZEA (Forschungszentrum Jülich) on a Vario EL cube, elemental
analyser (Elementar, Hanau, Germany). Experiments under microwave heating were performed using
a CEM Discover (Matthews, NC, USA) single-mode microwave reactor system.
Radioactivity on radio-TLC plates was detected on an InstantIMAGER and associated software
(Packard, Dreieich, Germany). Sep-Pak® C-18 plus-cartridges were purchased from Waters® (Eschborn,
Germany) and conditioned with 10 mL of ethanol and 10 mL water, while Sep-Pak® Light QMA
Carb-cartridges, also purchased from Waters®, were conditioned using 10 mL of water only.
Chromatographic systems: High-performance liquid chromatography (HPLC) was performed
on the following system from Dionex (Idstein, Germany): an Ultimate 3000 LPG-3400A HPLC pump,
an Ultimate 3000 VWD-3100 UV/VIS-detector, a UCI-50 chromatography interface, an injection
valve P/N 8215 and a NaI(Tl) well-type scintillation detector (Raytest, Straubenhardt, Germany) and
associated electronics for radioactivity detection. Data acquisition and interpretation were performed
with Chromeleon software (Thermo Scientific Dionex
out on a Knauer® HPLC-system comprising a Knauer Azura P 4.1S pump, a Knauer Azura UVD
2.1S UV/VIS-detector (Knauer, Berlin, Germany), a Rheodyne injector (20 L loop), and a NaI(Tl)
™, Version 6.8). Isocratic separations were carried
µ
well-type scintillation detector (EG&G Ortec; model 276 Photomultiplier Base) with an ACE Mate
Amplifier and BIAS supply (all from Ortek Ametek, Meerbusch, Germany) for radioactivity detection.
Data acquisition and interpretation were performed with Gina software (Raytest, Version 5.9 SP10).
Analytical HPLC was performed with the following columns:
a: Gemini 5
(Phenomenex, Aschaffenburg, Germany)
b: Luna 5 m C18(2) 100 Å with appropriate Luna C18 Security Guard 250 mm
(Phenomenex)
c: Luna 5 m PFP(2) 100 Å with appropriate Luna PFP(2) Security Guard 250 mm
µ
m C18 110 Å with appropriate Gemini C18 Security Guard 250 mm
×
×
×
4.6 mm
4.6 mm
4.6 mm
µ
µ
(Phenomenex)
In all cases elution was performed at a constant flow rate of 1 mL
min−1. UV and radioactivity
·
detectors were connected in series, corresponding to a time delay of 0.5–0.9 min depending on the flow
rate. 18F-Labelled compounds were identified by spiking the reaction mixture with corresponding
19F-reference compounds, using HPLC. The capacity factor values (k-values) of important radiolabelled
compounds together with the corresponding separation systems are summarized in Tables 1 and 2.
The Rf-values of important radiolabelled compounds and the corresponding TLC conditions are
summarized in Table 3.

Molecules 2016, 21, 1160
10 of 21
Table 1. Employed conditions of high performance liquid chromatography (HPLC) separations.
HPLC
Condition
Column
Eluent
Wavelength
Flow
Injection-Volume
1
2
3
4
5
6
7
c
b
c
a
a
a
a
40 MeCN:60 H2O
60 MeCN:40 H2O
A: H2O + 0.1% TEA, B: MeCN + 0.1% TEA
70 MeCN:30 H2O + 0.1% TEA
60 ACN:40 H2O + 0.1% TEA
A: H2O + 0.1% TEA B: MeCN + 0.1% TEA
A: H2O + 0.1% TEA B: MeCN + 0.1% TEA
254 nm
261 nm
261 nm
261 nm
261 nm
261 nm
261 nm
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
1 mL/min
20 µL
20 µL
20 µL
20 µL
20 µL
20 µL
20 µL
a
b
c
a gradient program of method 3: 0–16 min 70% A, 16–30 min 70%–50% A, 30–40 min 50% A, 40–41 min 50%–70%
A, 41–60 min 70% A; b gradient program of method 6: 0–10 min 40% A, 10–15 min 40%–20% A, 15–35 min
20% A, 35–40 min 20%–40% A, 40–60 min 40% A; c gradient program of method 7: 0–8 min 40% A, 8–15 min
40%–20% A, 15–40 min 20% A, 40–45 min 20%–40% A, 45–60 min 40% A.
Table 2. k-Values of 19F-reference compounds for HPLC-identification of labelled compounds.
Compound
HPLC-System
Condition
k-Values
6.7 (anisole), 7.3 (2-fluoroanisole),
9.3 (3-fluoroanisole), 8.2 (4-fluoroanisole)
Fluoroanisole
Knauer
1
15
21o
21m
21p
9
9
10
9
10
9
10
20
Knauer
Dionex
Dionex
Dionex
Knauer
Knauer
Knauer
Dionex
Dionex
Dionex
Dionex
Dionex
2
3
3
3
4
5
5
6
6
7
7
7
3.2
6.0
7.0
8.0
6.7
19.4
2.9
7.3
2.7
2.7
7.2
14.0
Table 3. Rf-values of relevant reference compounds for radio-thin layer chromatography (TLC) analyses.
Compound
Eluent
Rf
9
9 EE:1 PE + 1% TEA
9 EE:1 PE + 1% TEA
1 EE:4 PE
0.8
0.5
0.5
0.7
10
15
20
1 EE:4 PE
3.2. Radiochemistry
No-carrier-added [18F]fluoride was produced via the 18O(p,n)18F nuclear reaction by bombardment
of an isotopically enriched [18O]water target with 17 MeV protons at the JWS cyclotron BC 1710 in
house [34]. For all radiosyntheses 5 mL V-vials (Wheaton) were used. A Curiementor 2 dose calibrator
(PTW GmbH, Freiburg, Germany) was used for activity measurements. For all radio-HPLC analyses
(determination of RCY), activity was quantified by injection of a reference aliquot on a second injection
port behind the column, to measure the total activity of the aliquot (corrected for decay).
3.2.1. Radiosynthesis of tert-butyl-([18F]fluorophenethyl)carbamate ([18F]15)
The radiosyntheses during the developmental studies were typically performed with 30–60 MBq
n.c.a. [18F]fluoride which was preprocessed by standard procedures [28]. Differently, however, the
amounts of potassium carbonate and acetonitrile used were higher with 0.019 mmol and 1 mL,
respectively. After purging the reaction vessel with argon, a solution of 12 mg (25
µmol) of labelling
precursor 14 in 1 mL of dry DMF was added into the reaction vessel. During the reaction aliquots of

Molecules 2016, 21, 1160
11 of 21
20 µL were taken at various temperatures and quenched in 0.4 mL of water and acetonitrile (1:1 v/v).
Each mixture was analysed in triplicate by radio-TLC. The radiochemical yield was calculated from
the TLC-radiochromatogram and is defined as the ratio of radioactivity area of the desired product 15
(SiO2-TLC, EtOAc/PE 1:4 v/v, Rf 0.5) over the total area of fluorine-18 radioactivity which was placed
above the solvent front on the TLC-plate. For the examination of regioselectivity an aliquot of 500
µL
was removed for deprotection in presence of 100
µ
L of a 1 M HCl solution. After 10 min at 90 ◦C the
reaction vessel was cooled in an ice bath. The mixture was titrated with 1 M NaOH solution back on
pH 9 before an aliquot was taken for radio-HPLC measurements.
3.2.2. Radiosynthesis of 2-, 3- and 4-[18F]fluoroanisole
Typically 30–60 MBq of n.c.a. [18F]fluoride was prepared as described above for the radiosyntheses
of isomeric [18F]fluoroanisoles from corresponding ylide precursors, which was carried out as described
in the literature [29]. After completing the reaction, an aliquot was taken for radio-HPLC measurement
and for determination of regioselectivity.
3.2.3. Radiosynthesis of [18F]10 via the “Build-up” Synthesis
For the “build-up” synthesis of [18F]10 typically 200 MBq of [18F]fluoride was azeotropically dried
as described in 3.2.1 and the reaction vessel was purged with argon. A solution of 12 mg (25 µmol)
labelling precursor 14m and 1 mL of dry DMF was transferred into the V-vial. The mixture was stirred
at 110 ◦C for 10 min. After radiolabelling, the V-vial was cooled down in an ice bath and radioactivity
was measured. The mixture was diluted in 10 mL water, and the reaction vessel was rinsed with
0.3 mL DMF. The combined mixtures were transferred through a Sep-Pak® Plus C18 cartridge which
was previously conditioned with 10 mL of EtOH and 20 mL of water. Additionally 10 mL of water
were passed through the cartridge before 40 mL of air were purged through.
The intermediate compound [18F]15m was then eluted with 0.9 mL of dioxane from the reversed
phase resin into a new V-vial. For the deprotection 0.1 mL HCl-dioxane (4 M) were added, and the
◦
resulting mixture was stirred at room temperature for 2 min. After 15 min at 80 C and 70 mbar
under a stream of argon the mixture was cooled down to room temperature. Then 0.5 mL water
and 0.1 mL of an aqueous NaOH-solution (4 M) were added. The corresponding amine [18F]21 was
extracted three times with 1.0 mL of dichloromethane. The combined organic layers were dried by a
Na2SO4-cartridge (0.9 cm in diameter and 4.5 cm in length) and transferred into a new V-vial.
After evaporation of the solvent under reduced pressure the amine was converted by reductive
amination in presence of the aldehyde 8 (30 mg, 0.09 mmol) and sodium triacetoxyborohydride (30 mg,
0.14 mmol) in 0.5 mL of methanol to the pyrrole protected nNOS-inhibitor [18F]9. After 15 min at
room temperature the mixture was concentrated and alkalised with 0.1 mL of NaOH solution (4 M).
The product [18F]9 was extracted again with dichloromethane. The combined organic layers were
transferred into a microwave vessel and concentrated at 40 ◦C under a stream of argon. A solution
of 345 mg NH2OH HCl in 1 mL EtOH and 0.5 mL water was then added for the deprotection of the
·
pyrrole. This was carried out by microwave heating for 10 min at 100 ◦C (max. 50 W). Eventually,
an aliquot of the irradiated product was alkalised and analysed by radio-HPLC and radio-TLC. This
procedure yielded the desired nNOS-inhibitor [18F]10 in pure form.
3.2.4. Radiosynthesis of [18F]10 via “Late-Stage” Labelling
Different to the procedure described in Section 3.2.1. [18F]fluoride was preprocessed for radiosynthesis
as follows: an aliquot of approx. 100 MBq n.c.a. [18F]fluoride in 500
µ
L of water was purged through
a 46 mg QMA-cartridge (Waters®, Sep-Pak Accell Plus QMA Carbonate Plus Light). After rinsing
the cartridge with 1 mL of methanol a solution of 2.6 mol of TEAHCO3 in 0.8 mL of methanol was
µ
slowly (1 min) passed through the resin into a V-vial. The vial was equipped with a cannula and sterile
filter. At 80 ◦C and 250 mbar the solvent was removed in 5 min under a stream of air. Afterwards,

Molecules 2016, 21, 1160
12 of 21
the cannula was removed and the pressure was lowered to 6–12 mbar for 5 min. The vial was then
ventilated by the cannula again and cooled to RT. For radiolabelling a solution of 30 L of acetonitrile,
10 mg (15 mol) of precursor 19 and 3.5 mg (5 L of DMF was added.
mol) of CuIIOTf2py4 in 300
µ
µ
µ
µ
The mixture was stirred for 10 min at 120 ◦C. During the reaction the cannula was not removed.
After radiofluorination the mixture was completely transferred into 50 mL of water (reactor
was rinsed with 0.5 mL of ethanol). The aqueous product mixture was then rinsed through a C18
cartridge (Waters®, SepPak, 500 mg), and 10 mL of water and 40 mL of air were purged through
the resin. The product was eluted from the resin into a microwave vessel with 3 mL of ethanol.
A solution of 345 mg of NH2OH
out by microwave heating for 10 min at 100 C (max. 50 W), and then the mixture alkalised with
·
HCl in 1 mL water was added. Subsequent deprotection was carried
◦
a NaOH-solution (pH >9) and diluted with 50 mL of water containing 0.5 wt % of Na3PO4 12H2O
·
(titrated with concentrated H3PO4 to pH 8.5). The product was trapped on the C18 cartridge (Waters®,
SepPak, 500 mg) by passing the aqueous mixture though the resin. 10 mL of water and 40 mL air
were purged through it before elution of the product with 3 mL acetonitrile, yielding the desired
nNOS-tracer [18F]10 in radiochemically pure form. The molar activity of [18F]10 after preparation by
both methods was measured by determination of product mass and activity, using the HPLC system
‘Dionex’ and condition ‘7’ as listed above in Tables 1 and 2, respectively.
3.3. Precursor Syntheses
3.3.1. Synthesis of Iodonium Ylide Precursors
General procedure for the Reduction of Nitriles
The compounds 22o, 22m and 22p were prepared as described in the literature [35,36].
2-Iodophenylethylamine hydrochloride (12o)
Analytical data correspond to the reported spectroscopic values in literature [36].
3-Iodophenylethylamine hydrochloride (12m)
1H-NMR (200.13 MHz, DMSO-d6) 8.30 (b, 3H), 7.64 (m, 2H), 7.31 (d, 3J = 7.5 Hz, 1H), 7.14 (t, 3J = 7.5 Hz,
δ
1H), 2.91–3.06 (m, 4H). 13C-NMR (50.33 MHz, DMSO-d6)
δ 140.7, 137.7, 135.9, 131.2, 128.7, 95.7, 40.1,
32.8. HRMS (C8H10IN, [M + H]+) calcd: 247.9931, found: 247.9931. EA calcd: C (33.89), H (3.91), N
(4.94), found: C (34.14 ± 0.13), H (3.95 ± 0.02), N (4.78 ± 0.02).
4-Iodophenylethylamine hydrochloride (12p)
1H-NMR (600.15 MHz, DMSO-d6)
δ
8.16 (b, 3H), 7.68 (d, 3J = 6.0 Hz, 2H), 7.10 (d, 3J = 6.0 Hz, 2H), 3.00
(t, 3J = 6.5 Hz, 2H), 2.87 (t, 3J = 6.5 Hz, 2H). 13C-NMR (150.92 MHz, DMSO-d6)
δ 137.8, 137.7, 131.6,
93.1, 40.0, 32.9. HRMS (C8H10IN, [M + H]+) calcd: 247.9931, found: 247.9930.

Molecules 2016, 21, 1160
13 of 21
General Procedure for Boc-Protection of 13
A mixture of 283 mg (1 mmol) iodophenethylamine hydrochloride, 218 mg (1 mmol) Boc2O
and 250 mg (3 mmol) NaHCO3 in 5 mL methanol was treated with ultrasound for 30 min at 50 ◦C.
After filtration and removal of the solvent under reduced pressure, the crude product was purified
by flash chromatography (petroleum ether/20% ethyl acetate, Rf = 0.6 (ortho, para), Rf = 0.5 (meta)) to
obtain the product as a colourless oil (yields: 13o: 306 mg, 0.88 mmol, 88%; 13m: 326 mg, 0.94 mmol,
94%; 13p: 333 mg, 0.96 mmol, 96%).
tert-Butyl-(2-iodophenethyl)carbamate (13o)
Analytical data correspond to the reported spectroscopic values in literature [36].
tert-Butyl-(3-iodophenylethyl)carbamate (13m) [37]
1H-NMR (200.13 MHz, CDCl3)
δ
7.61–7.58 (m, 2H), 7.21–7.03 (m, 2H), 4.66 (b, 1H), 3.38 (t, 3J = 6.7 Hz,
155.8, 141.5, 137.8, 135.5,
2H), 2.77 (t, 3J = 7.0 Hz, 2H), 1.48 (s, 9H). 13C-NMR (50.33 MHz, CDCl3)
δ
130.3, 128.1, 94.6, 79.3, 42.1, 35.8, 28.4. HRMS (C13H18INO2) calcd: 348.0455 [M + H]+, 370.0291
[M + Na]+, found: 348.0451[M + H]+, 370.0282 [M + Na]+. EA calcd: C (44.97), H (5.23), N (4.03), found:
C (44.64 ± 0.11), H (5.18 ± 0.02), N (3.65 ± 0.08).
tert-Butyl-(4-iodophenethyl)carbamate (13p)
1H-NMR (200.13 MHz, CDCl3)
δ
7.64 (dt, 3J = 8.4 Hz, 4J = 1.9 Hz, 2H), 7.32 (dt, 3J = 8.4 Hz, 4J = 1.9 Hz,
2H), 4.45 (b, 1H), 3.37 (t, 3J = 6.9 Hz, 2H), 2.77 (t, 3J = 7.0 Hz, 2H), 1.46 (s, 9H). 13C-NMR (50.32 MHz,
CDCl3)
δ 155.9, 138.7, 137.6, 130.9, 91.6, 79.4, 41.8, 35.8, 28.4. HRMS (C13H18INO2) calcd: 348.0455
[M + H]+, 370.0274 [M + Na]+, found 348.0467 [M + H]+, 370.0291 [M + Na]+. EA calcd: C (44.97), H
(5.23), N (4.03), found: C (45.29 ± 0.04), H (5.24 ± 0.01), N (3.75 ± 0.03).
tert-Butyl-(fluorophenethyl)carbamate (15)
A stirred mixture of 139 mg (1 mmol) fluorophenethylamine and 218 mg (1 mmol) Boc2O in 2 mL
◦
methanol was treated with ultrasound for 30 min at 50 C. After removal of the solvent under reduced
pressure the crude product was purified by flash chromatography (petroleum ether/20% ethyl acetate,
Rf = 0.6 (ortho, para), 0.5 (meta)) to obtain the product as a colourless oil (yields: 15o: 232 mg, 0.97 mmol,
97%; 15m: 234 mg, 0.98 mmol, 98%; 15p: 229 mg, 0.96 mmol, 96%).
tert-Butyl-(2-fluorophenethyl)carbamate (15o)

Molecules 2016, 21, 1160
14 of 21
3
1H-NMR (200.13 MHz, CDCl3)
δ
7.00–7.30 (m, 4H), 4.70 (b, 1H), 3.40 (t, J = 7.0 Hz, 2H), 2.87 (t,
161.3 (d, 1JCF = 245 Hz), 155.9, 131.2 (d,
3J = 7.0 Hz, 2H), 1.46 (s, 9H). 13C-NMR (50.33 MHz, CDCl3)
δ
3JCF = 5 Hz), 128.2 (d, 3JCF = 8 Hz), 125.9 (2JCF = 16 Hz), 124.1 (d, 4JCF = 4 Hz), 115.3 (d, 2JCF = 22 Hz),
79.3, 40.8, 29.8, 28.4. 19F-NMR (188.31 MHz, CDCl3) δ −118.6. HRMS (C13H18FNO2) calcd: 240.1394
[M + H]+, 370.0291 [M + Na]+, found: 240.1393 [M + H]+, 262.1214 [M + Na]+. EA calcd: C (65.25), H
(7.58), N (5.85), found: C (65.03 ± 0.04), H (7.62 ± 0.06), N (5.85 ± 0.05).
tert-Butyl-(3-fluorophenethyl)carbamate (15m)
1
UV-absorption (
λ
max, nm) 210, 261. H-NMR (200.13 MHz, CDCl3)
δ
7.23–7.20 (m, 1H), 6.99–6.87 (m,
3H), 4.75 (b, 1H), 3.36 (t, 3J = 6.9 Hz), 2.79 (t, 3J = 7.0 Hz), 1.44 (s, 9H). 13C-NMR (50.33 MHz, CDCl3)
162.5 (d, 1JCF = 246 Hz), 155.9, 141.6 (d, 3JCF = 7 Hz), 129.9 (d, 3JCF = 8 Hz), 124.4 (d, 4JCF = 3 Hz), 115.6
δ
(d, 2JCF = 21 Hz), 113.2 (d, 2JCF = 21 Hz), 79.3, 41.8, 36.0, 28.4. 19F-NMR (188.31 MHz, CDCl3)
−
113.4.
HRMS (C13H18FNNaO2) calcd: 262.1214 [M + Na]+, found: 262.1222 [M + Na]+. EA calcd: C (65.25), H
(7.58), N (5.85), found: C (65.24 ± 0.10), H (7.55 ± 0.01), N (5.78 ± 0.03).
tert-Butyl-(4-fluorophenethyl)carbamate (15p)
1H-NMR (200.13 MHz, CDCl3)
δ
7.16 (t, 3J = 6.0 Hz, 2H), 7.01 (t, 3J = 6.6 Hz, 2H), 4.60 (b, 1H), 3.36
(t, J = 7.0 Hz, 2H), 2.79 (t, J = 7.0 Hz, 2H), 1.46 (s, 9H). 13C-NMR (50.32 MHz, CDCl3)
δ
161.6 (d,
3
3
1JCF = 244 Hz), 155.9, 134.7 (d, 4JCF = 3 Hz), 130.2 (d, 3JCF = 8 Hz), 115.3 (d, 2JCF = 21 Hz), 113.2 (d,
2JCF = 21 Hz), 79.3, 42.1, 35.5, 28.4. 19F-NMR (188.31 MHz, CDCl3) δ −117.4. HRMS (C13H18FNNaO2)
calcd: 262.1214 [M + Na]+, found: 262.1215 [M + Na]+. EA calcd: C (65.25), H (7.58), N (5.85), found: C
(65.29 ± 0.19), H (7.65 ± 0.03), N (5.78 ± 0.02).
General Procedure for the Synthesis of Iodonium Ylides from Aryliodides
In a 50 mL round bottom flask, 1.00 g (2.88 mmol) tert-butyl(iodophenethyl)carbamate and 662 mg
(2.88 mmol) of m-CPBA were suspended in 8 mL of DCM and stirred for 2 h at room temperature. In a
separate vessel 498 mg (3.45 mmol) of Meldrum’s acid and 960 mg (17.11 mmol) of KOH were stirred
in 8 mL of DCM for 15 min. Then the mixture containing the oxidized iodobenzene was added to
the potassium salt of Meldrum’s acid. Remaining solids were suspended in 5 mL of DCM and also
added. After 3 h stirring at RT the mixture was filtered over cellulose, the filter washed with 40 mL of
DCM and the filtrates concentrated under reduced pressure. The crude product was purified by flash
chromatography with ethyl acetate and acetone (1:1 v/v) for the meta-derivative (14m Rf = 0.5) or with
100% ethyl acetate for the ortho- and para-isomers (14o Rf = 0.4 and 14p Rf = 0.2), to obtain the product
as a slightly yellow solid (yields: 14o: 648 mg, 1.32 mmol, 46%; 14m: 606 mg, 1.24 mmol, 43%; 14p
:
634 mg, 1.30 mmol, 45%).
2-tert-Butoxycarbonylaminoethylphenyl-iodonium-(5-[2,2-dimethyl-1,3-dioxane-4,6-dione]) ylide (14o)
O
O
O
N
O
H
I
O
O

Molecules 2016, 21, 1160
15 of 21
1H-NMR (600.15 MHz, DMSO-d6)
δ
7.95 (d, 3J = 6.0 Hz), 7.52 (t, 3J = 6.0 Hz, 1H), 7.42 (d, 3J = 6.0 Hz,
1H), 7.26 (t, 3J = 6.0 Hz, 1H), 3.28 (t, 3J = 6.0 Hz, 1H), 3.06 (t, 3J = 6.0 Hz, 1H), 1.52 (s, 6H), 1.37 (s, 9H).
13C-NMR (150.92 MHz, DMSO-d6)
δ 163.2, 156.1, 141.4, 136.6, 132.0, 130.7, 129.5, 122.6, 103.1, 78.2,
59.2, 41.0, 38.5, 28.4, 25.7. HRMS (C19H24INO6) calcd: 512.0541 [M + Na]+, 528.0280 [M + K]+, found
512.0547 [M + Na]+, 528.0286 [M + K]+. EA calcd: C (46.64), H (4.94), N (2.86), found: C (47.20
±
0.10),
H (5.48 ± 0.02), N (2.75 ± 0.03).
3-tert-Butoxycarbonylaminoethylphenyl-iodonium-(5-[2,2-dimethyl-1,3-dioxane-4,6-dione]) ylide (14m)
1H-NMR (200.13 MHz, DMSO-d6)
δ
7.68–7.62 (m, 2H), 7.40–7.37 (m, 2H), 3.16 (t, 3J = 6.7 Hz, 2H), 2.73 (t,
163.3, 156.0, 143.1, 133.0,
3J = 6.9 Hz, 2H), 1.59 (s, 6H), 1.38 (s, 9H). 13C-NMR (50.33 MHz, DMSO-d6)
δ
131.3, 130.7, 116.8, 103.2, 102.5, 78.1, 58.2, 41.6, 35.6, 28.4, 25.8. HRMS (C19H24INO6) calcd: 490.0721
[M + H]+, 528.0280 [M + K]+, found: 490.0724 [M + H]+, 528.0282 [M + K]+. EA calcd: C (46.64), H
(4.94), N (2.86), found: C (46.10 ± 0.09), H (5.05 ± 0.04), N (3.06 ± 0.05).
4-tert-Butoxycarbonylaminoethylphenyl-iodonium-(5-[2,2-dimethyl-1,3-dioxane-4,6-dione]) ylide (14p)
1H-NMR (200.13 MHz, DMSO-d6)
δ
7.73 (d, 3J = 8.4 Hz, 2H), 7.28 (d, 3J = 8.4 Hz, 2H), 3.17 (t, 3J = 6.8 Hz,
163.4, 156.1,
2H), 2.73 (t, 3J = 6.9 Hz, 2H), 1.58 (s, 6H), 1.36 (s, 9H). 13C-NMR (50.33 MHz, DMSO-d6)
δ
143.2, 133.1, 131.7, 113.2, 103.3, 78.1, 58.3, 41.3, 35.4, 28.5, 25.9. HRMS (C19H24INO6) calcd: 490.0721
[M + H]+, 512.0541 [M + Na]+, found: 490.0721 [M + H]+, 512.0592 [M + Na]+. EA calcd: C (46.64), H
(4.94), N (2.86). Found: C (46.59 ± 0.05), H (5.24 ± 0.02), N (2.98 ± 0.02).
In case of the isomeric iodonium ylides of anisole 1.5 g (6.45 mmol) of the corresponding
iodoanisole was used as starting amount, following otherwise the general procedure given above
(yields: ortho-anisole ylide: 1.070 g, 2.84 mmol, 44%; meta-anisole ylide: 1.010 g, 2.68 mmol, 42%;
para-anisole ylide: 978 mg, 2.60 mmol, 41%).
2-Methoxyphenyl-iodonium-(5-[2,2-dimethyl-1,3-dioxane-4,6-dione]) ylide
Analytical data correspond to the reported spectroscopic values in literature [29].
3-Methoxyphenyl-iodonium-(5-[2,2-dimethyl-1,3-dioxane-4,6-dione]) ylide

Molecules 2016, 21, 1160
16 of 21
Analytical data correspond to the reported spectroscopic values in literature [29].
4-Methoxyphenyl-iodonium-(5-[2,2-dimethyl-1,3-dioxane-4,6-dione]) ylide
Analytical data correspond to the reported spectroscopic values in literature [29].
3.3.2. Synthesis of Reference Compounds and Iodinated Intermediates for the Preparation of the
Boronic Ester Precursor
Compounds 4, 6, 7 and 8 were prepared as described in the literature [25].
N-(3-((6-(2,5-Dimethyl-1H-pyrrol-1-yl)-4-methylpyridin-2-yl)methoxy)benzyl)-2-
(3-fluorophenyl)ethanamine (9)
To a solution of 153 mg (1.1 mmol) of 3-fluorophenethyl amine in 4 mL of dry methanol 320 mg
(1 mmol) of 3-((6-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methylpyridin-2-yl)methoxy)-benzaldehyde in 2 mL
of dry methanol were added dropwise. Then 424 mg (2 mmol) of NaBH(OAc)3 were added carefully,
and the mixture was allowed to react at room temperature for 1 h. After filtration and removal of the
solvent, the residue was diluted with 15 mL of 1 N NaOH and extracted with CH2Cl2 (3
×
10 mL).
The organic layers were combined, washed with brine, dried over NaSO4, and concentrated under
reduced pressure to give the crude product, which was purified by flash chromatography (ethyl
acetate/9% petroleum ether/1% triethyl amine) to receive a pale yellow oil in 89% yield (395 mg,
0.89 mmol).
Analytical data correspond to the reported spectroscopic values in literature [25].
N-(3-((6-(2,5-Dimethyl-1H-pyrrol-1-yl)-4-methylpyridin-2-yl)methoxy)benzyl)-2-
(3-iodophenyl)ethan-1-amine (17)
Compound 17 was synthesized by the same method as compound 9, using 3-iodophenethyl
amine as reactant. The product 17 was obtained as pale yellow oil in 87% yield.
I
O
N
N
N
H
1H-NMR (600.15 MHz, DMSO-d6)
δ
7.77 (s, 1H), 7.70 (d, 3J = 7.8 Hz, 1H), 7.57 (s, 1H), 7.40–7.36 (m,
3H), 7.24 (t, 3J = 7.8 Hz, 1H), 7.16 (s, 1H), 7.07–7.04 (m, 2H), 5.97 (s, 2H), 5.32 (s, 2H), 3.84 (s, 2H), 2.84
(m, 4H), 2.59 (s, 3H), 2.34 (b, 1H), 2.23 (s, 6H). 13C-NMR (150.92 MHz, DMSO-d6) δ 158.1, 156.4, 150.7,
150.6, 143.5, 142.8, 137.2, 134.5, 130.3, 129.1, 128.1, 127.7, 121.3, 121.1, 120.5, 114.2, 112.8, 106.6, 94.7, 69.7,
52.6, 49.9, 35.2, 20.5, 13.0. HRMS (C28H30IN3O) calcd: 552.1501 [M + H]+, found: 552.1504 [M + H]+.
EA calcd: C (60.98), H (5.48), N (7.62), found: C (61.06 ± 0.02), H (5.56 ± 0.01), N (7.36 ± 0.03).

Molecules 2016, 21, 1160
17 of 21
6-((3-((3-Fluorophenethylamino)methyl)phenoxy)methyl)-4-methylpyridin-2-amine (10)
This compound was prepared as described in literature [25].
Analytical data correspond to the reported spectroscopic values in literature [25].
tert-Butyl-(3-((6-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methylpyridin-2-yl)methoxy)benzyl)(3-fluorophenethyl)-
carbamate (20)
A stirred mixture of 398 mg (0.90 mmol) of 9, 218 mg (1.00 mmol) of Boc2O and 5 mg (0.04 mmol)
of DMAP in 8 mL of methanol was stirred at RT for 15 min. After removal of the solvent under reduced
pressure the crude product was purified by flash chromatography (petroleum ether/20% ethyl acetate,
Rf = 0.7) to obtain the product as a colourless oil in 84% yield (410 mg, 0.76 mmol).
1H-NMR (600.15 MHz, DMSO-d6, mixture of rotamers)
δ 7.37 (br, 1H), 7.32–7.28 (m, 1H), 7.26 (t,
3J = 7.8 Hz, 1H), 7.17 (s, 1H), 7.01–6.95 (m, 3H), 6.94–6.92 (m, 1H), 6.89–6.87 (m, 1H), 6.84–6.83 (m, 1H),
5.78 (s, 2H), 5.15 (s, 2H), 4.34–4.30 (m, 2H), 3.33–3.32 (m, 2H), 2.74–2.73 (m, 2H), 2.39 (s, 3H), 2.03 (s,
6H), 1.32 (s, 9H). 13C-NMR (150.92 MHz, DMSO-d6, mixture of rotamers)
δ
162.1 (d, 1JCF = 243.1 Hz),
3
158.2, 156.3, 154.8 and 154.5, 150.7, 150.6, 142.1 and 142.1, 140.5 and 140.2, 130.1 (d, JCF = 8.1 Hz),
129.6, 127.6, 124.9 and 124.8, 121.3, 121.0, 120.0 and 119.8, 115.5 and 115.4, 114.0 and 113.6, 113.3, 112.8
(d, 2JCF = 8.1 Hz), 106.6, 78.8 and 78.7, 69.7, 50.0 and 48.8, 47.6 and 47.5, 33.6 and 33.2, 27.9 and 27.8,
20.5, 13.0. 19F-NMR (188.31 MHz, DMSO-d6, mixture of rotamers)
−
113.899 and
−
113.891. HRMS
(C33H38FN3O3) calcd: 544.2970 [M + H]+, found: 544.2970 [M + H]+. EA calcd: C (72.40), H (7.04), N
(7.73), found: C (72.66 ± 0.08), H (7.18 ± 0.03), N (7.73 ± 0.07).
tert-Butyl-(3-((6-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methylpyridin-2-yl)methoxy)benzyl)
(3-iodophenethyl)carbamate (18)
Compound 18 was synthesized via the same method as compound 20, using 1.3 g (2.36 mmol) 17
as reactant. The product 18 was obtained as pale yellow oil in 87% yield (1.34 g, 2.05 mmol).
1H-NMR (600.15 MHz, DMSO-d6, mixture of rotamers)
δ 7.56–7.53 (m, 2H), 7.37 (s, 1H), 7.26 (t,
3
3J = 7.8 Hz, 1H), 7.17–7.13 (m, 2H), 7.07 (t, J = 7.8 Hz, 1H), 6.94–6.92 (m, 1H), 6.90–6.87 (m, 1H),
6.84–6.83 (m, 1H), 5.78 (s, 2H), 5.15 (s, 2H), 4.34–4.29 (m, 2H), 3.31–3.24 (m, 2H), 2.68–2.67 (m, 2H), 2.39
(s, 3H), 2.03 (s, 6H), 1.32 (s, 9H). 13C-NMR (150.92 MHz, DMSO-d6, mixture of rotamers)
δ 158.2, 156.3,
154.8 and 154.5, 150.7, 150.6, 142.0 and 141.8, 140.5 and 140.3, 137.4 and 137.3, 134.8, 130.4, 129.6, 128.3
and 128.2, 127.6, 121.3, 121.0, 120.0 and 119.8, 114.0 and 113.6, 113.3, 106.6, 94.9, 78.9 and 78.7, 69.7, 50.0
and 48.7, 47.7 and 47.5, 33.4and 33.1, 27.9 and 27.8, 20.5, 13.0. HRMS (C33H38IN3O3) calcd: 652.2031
[M + H]+, found: 652.2033 [M + H]+. EA calcd: C (60.83), H (5.88), N (6.45). Found: C (60.87
(5.90 ± 0.02), N (6.25 ± 0.02).
±
0.11), H

Molecules 2016, 21, 1160
18 of 21
3.3.3. Synthesis of the Tetrakis(pyridine)copper(II)triflate-complex
This compound was prepared as described in literature [38].
F
F
O
F
S
Cu2+
O
N
O
2
4
Analytical data correspond to the reported spectroscopic values in literature [38].
3.3.4. Synthesis of the Boronic Ester Precursor tert-Butyl(3-((6-(2,5-dimethyl-1H-pyrrol-1-yl)-4-
methylpyridin-2-yl)methoxy)benzyl)(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylethyl)-
carbamate (19)
A suspension of 420 mg (0.645 mmol) of the iodide 18, 273 mg (1.074 mmol) of
bis-pinacolatodiborane, 152 mg (1.548 mmol) of potassium acetate and 15 mg (0.02 mmol) of
[1,1’-bis(diphenylphosphino)ferrocene]dichloropalladium(II) in 4 mL of DMF was heated at 85 ◦C for
90 min. The progress of reaction was tested by TLC using 10% ethyl acetate in toluene as mobile phase
(Rf (18) = 0.6; Rf (19) = 0.5). After filtration through a Celite® pad and elution with diethyl ether the
◦
mixture was concentrated in vacuo at 60 C. The residue was diluted with diethyl ether, and activated
carbon powder and Celite® were added. After stirring for 10 min the suspension was filtered through a
Celite®/Cellulose (1:1) pad and eluted with diethyl ether. After removal of the solvent under reduced
pressure the pale yellow residue was further purified by reversed phase flash chromatography (100%
acetonitrile, Rf = 0.5) to obtain the product as a white solid in 64% yield (271 mg, 0.416 mmol).
1H-NMR (600.15 MHz, d6-DMSO, mixture of rotamers)
δ 7.51–7.49 (m, 2H), 7.36 (br, 1H), 7.29–7.21
(m, 3H), 7.16 (s, 1H), 6.93–6.92 (m, 1H), 6.88–6.86 (m, 1H), 6.83–6.81 (m, 1H), 5.77 (s, 2H), 5.15 (s, 2H),
4.36–4.29 (m, 2H), 3.30 (t, 3J = 7.2 Hz, 2H), 2.73–2.71 (m, 2H), 2.38 (s, 3H), 2.02 (s, 6H), 1.32 (s, 9H), 1.27
(s, 12H). 13C-NMR (150.92 MHz, DMSO-d6, mixture of rotamers)
δ 158.2, 156.3, 154.9 and 154.5, 150.7,
150.6, 140.6 and 140.3, 138.5, 134.9 and 134.8, 132.2, 131.9 and 131.8, 129.6, 128.5, 127.8, 127.6, 121.3,
121.1, 120.0 and 119.7, 113.9 and 113.5, 113.3, 106.6, 83.5, 78.8 and 78.7, 69.7, 50.0 and 48.6, 48.2 and 47.7,
33.8 and 33.5, 27.9 and 27.8, 24.6, 20.5, 13.0. 11B-NMR (128.37, d6-DMSO, mixture of rotamers)
δ 28.9
(br). HRMS (C39H50BN3O5) calcd: 652.3916 [M + H]+, found: 652.3915 [M + H]+. EA calcd: C (71.88),
H (7.73), N (6.45), found: C (71.53 ± 0.06), H (7.71 ± 0.03), N (6.41 ± 0.03).
4. Summary and Conclusions
The synthesis of an 18F-labelled aminopyridine derived nNOS-inhibitor was developed here, in
order to provide a radioprobe for in vivo imaging studies of the enzyme activity. The preparation of the
desired product [18F]10 was successfully achieved by two alternative newer radiosynthesis methods.
The pathway from an iodonium ylide precursor allowed for an efficient nucleophilic
18F-functionalisation of an aromatic building block which was further converted to the desired
nNOS-inhibitor. Iodonium ylides are ideal precursors for 18F-fluorination as they are stable to air and
moisture. In order to test for isomerisation processes different positional isomers of the iodonium
ylide precursor were synthesized with easy work-up procedures and comparatively high overall
yields of about 43%. Their radiofluorination proceeded regioselectively and efficiently with high

Molecules 2016, 21, 1160
19 of 21
radiochemical yields of about 78%. The subsequent “build-up” synthesis in 4 steps yielded the desired
nNOS-inhibitor [18F]10 in about 15% RCY based on starting [18F]fluoride.
Alternatively, with regard to a suitability of the radiofluorination method for automated
synthesizers and microfluidic systems, a “late-stage”, two-step procedure for the preparation of the
nNOS-tracer was studied based on the copper-mediated 18F-fluorination of a corresponding boronic
acid ester precursor. The n.c.a. 18F-exchange of a dioxaborolane group succeeded with radiochemical
yields of up to 53%. A microwave assisted displacement of protecting groups then led to about 15%
RCY of [18F]10, based on starting [18F]fluoride. Thus, the present study is also a further example for
the applicability of this relatively new, very promising n.c.a. radiofluorination method.
So far, there exist only a few effective “late-stage” labelling methods for n.c.a. 18F-fluorination of
non-activated arenes. Often, those are limited by the preparative possibilities of suitable, corresponding
precursors, especially of highly functionalized compounds. Considering that this study focused on
the preparation of the inhibitor [18F]10 for further preclinical evaluation, both labelling routes were
not optimized to the same level, and thus a conclusive comparison of the methods cannot be given.
This would demand an evaluation of many more compounds 18F-labelled by those processes under
comparable conditions and efforts, respectively. Following remarks, however, might be of interest.
Beneficially, ylide precursors are easy to handle and render high radiofluorination yields which are
possible without the need of metal catalysts. However, their production requires oxidative conditions,
why nitrogen containing compounds sometimes cannot be converted into their corresponding
iodine(III)-intermediates. A recent publication on radiofluorination of spirocyclic iodonium ylides,
however, demonstrated the possibility to produce precursors from a variety of nitrogen- and
oxygen-containing heterocycles [39], expanding the scope of electron-rich and sterically hindered
[18F]fluoroarenes [40]. Further on, ylides of complex precursors were already shown for some time to
be accessible [41]. Thus, both types of precursors used here would in principle allow the nucleophilic
18F-exchange in a late synthetic step. Indeed, the iodinated intermediate 18 supposedly enables its
conversion to a spirocyclic iodonium ylide as well as to a dioxaborolane. This would allow to directly
compare both types of precursors in further studies on a “late-stage” radiofluorination of compound 10
.
The chemoselective preparation of a corresponding dioxaborolane as precursor offers probably
complimentary possibilities to ylides, depending on the composition of functional groups of the
compound to be labelled. At the end, the composition of the compound will determine the accessibility
of a desired ylide or boronic acid precursor. In this study it was found that the borylation conditions
should be carefully optimized and that highly reactive iodides lend preferably to reach high yields and
pure products. In contrast, when starting from corresponding bromides, the isolation of the product
was difficult after the Miyaura borylation, if the conversion was not quantitatively completed.
At the present stage of optimization devoted, the radiochemical yield of the nNOS inhibitor
[18F]10, after “build-up” process and “late-stage” labelling, was directly comparable. Although
potential for improvement seems warranted, both methods sufficiently provide the desired inhibitor
as probe for further preclinical imaging studies with PET, aiming at the determination of the activity
of nNOS.
Acknowledgments: The authors are grateful to the Michael J. Welch Foundation, recognising and honoring
this project with the “Hot Atom Found Outstanding Trainee Award”. Furthermore, they wish to thank D. Bier
and M. Holschbach (INM-5), S. Willbold and B. Santiago-Schübel (Zentralinstitut für Engeneering, Elektronik
und Analytik, ZEA-3) for recording the spectroscopic data; the operators of the JSW BC1710 cyclotron (INM-5),
all Forschungszentrum Jülich, for the routine production of fluorine-18.
Author Contributions: C.D., J.E. and H.H.C. conceived of and designed the study. C.D. performed the
experiments, while all authors participated in data interpretation, writing and revising the manuscript. All authors
approved the submitted and revised article.
Conflicts of Interest: The authors declare no conflict of interest.

Molecules 2016, 21, 1160
20 of 21
References
1.
Thomas, D.D.; Ridnour, L.A.; Isenberg, J.S.; Flores-Santana, W.; Switzer, C.H.; Donzelli, S.; Hussain, P.;
Vecoli, C.; Paolocci, N.; Ambs, S.; et al. The chemical biology of nitric oxide: Implications in cellular signaling.
Free Radic. Biol. Med. 2008, 45, 18–31. [CrossRef] [PubMed]
2.
3.
Alderton, W.K.; Cooper, C.E.; Knowles, R.G. Nitric oxide synthases: Structure, function and inhibition.
Biochem. J. 2001, 357, 593–615. [CrossRef] [PubMed]
Michel, T.; Feron, O. Nitric oxide synthases: Which, where, how, and why? J. Clin. Investig. 1997, 100,
2146–2152. [CrossRef] [PubMed]
4.
5.
6.
Titheradge, M.A. Nitric oxide in septic shock. Biochim. Biophys. Acta 1999, 1411, 437–455. [CrossRef]
Ashutosh, K. Nitric oxide and asthma: A review. Curr. Opin. Pulm. Med. 2000, 6, 21–25. [CrossRef] [PubMed]
Hobbs, A.J.; Higgs, A.; Moncada, S. Inhibition of nitric oxide synthase as a potential therapeutic target.
Annu. Rev. Pharmacol. Toxicol. 1999, 39, 191–220. [CrossRef] [PubMed]
7.
8.
9.
Moore, D.J.; West, A.B.; Dawson, V.L.; Dawson, T.M. Molecular pathophysiology of Parkinson’s disease.
Annu. Rev. Neurosci. 2005, 28, 57–87. [CrossRef] [PubMed]
Li, H.; Forstermann, U. Nitric oxide in the pathogenesis of vascular disease. J. Pathol. 2000, 190, 244–254.
[CrossRef]
Xu, W.; Liu, L.Z.; Loizidou, M.; Ahmed, M.; Charles, I.G. The role of nitric oxide in cancer. Cell Res. 2002, 12,
311–320. [CrossRef] [PubMed]
10. Lechner, M.; Lirk, P.; Rieder, J. Inducible nitric oxide synthase (iNOS) in tumor biology: The two sides of the
same coin. Semin. Cancer Biol. 2005, 15, 277–289. [CrossRef] [PubMed]
11. Vannini, F.; Kashfi, K.; Nath, N. The dual role of iNOS in cancer. Redox Biol. 2015, 6, 334–343. [CrossRef]
[PubMed]
12. Zhang, L.; Dawson, V.L.; Dawson, T.M. Role of nitric oxide in Parkinson’s disease. Pharmacol. Ther. 2006, 109,
33–41. [CrossRef] [PubMed]
13. Fernandez, A.P.; Pozo-Rodrigalvarez, A.; Serrano, J.; Martinez-Murillo, R. Nitric oxide: Target for therapeutic
strategies in Alzheimer’s disease. Curr. Pharm. Des. 2010, 16, 2837–2850. [CrossRef] [PubMed]
14. Deckel, A.W. Nitric oxide and nitric oxide synthase in Huntington’s disease. J. Neurosci. Res. 2001, 64, 99–107.
[CrossRef] [PubMed]
15. Smith, K.J.; Lassmann, H. The role of nitric oxide in multiple sclerosis. Lancet Neurol. 2002, 1, 232–241.
[CrossRef]
16. Ashina, M. Nitric oxide synthase inhibitors for the treatment of chronic tension-type headache.
Expert Opin. Pharmacother. 2002, 3, 395–399. [CrossRef] [PubMed]
17. Sims, N.R.; Anderson, M.F. Mitochondrial contributions to tissue damage in stroke. Neurochem. Int. 2002, 40,
511–526. [CrossRef]
18. Erdal, E.P.; Litzinger, E.A.; Seo, J.; Zhu, Y.; Ji, H.; Silverman, R.B. Selective neuronal nitric oxide synthase
inhibitors. Curr. Top. Med. Chem. 2005, 5, 603–624. [CrossRef] [PubMed]
19. Yang, Y.; Yu, T.; Lian, Y.J.; Ma, R.; Yang, S.; Cho, J.Y. Nitric oxide synthase inhibitors: A review of patents
from 2011 to the present. Expert Opin. Ther. Pat. 2015, 25, 49–68. [CrossRef] [PubMed]
20. Maddaford, S.; Annedi, S.C.; Ramnauth, J.; Rakhit, S. Advancements in the development of nitric oxide
synthase inhibitors. In Annual Reports in Medicinal Chemistry; John, E.M., Ed.; Academic Press: Foster City,
CA, USA, 2009; Volume 44, pp. 27–50.
21. Vallance, P.; Leiper, J. Blocking NO synthesis: How, where and why? Nat. Rev. Drug Discov. 2002, 1, 939–950.
[CrossRef] [PubMed]
22. Lawton, G.R.; Ralay Ranaivo, H.; Chico, L.K.; Ji, H.; Xue, F.; Martasek, P.; Roman, L.J.; Watterson, D.M.;
Silverman, R.B. Analogues of 2-aminopyridine-based selective inhibitors of neuronal nitric oxide synthase
with increased bioavailability. Bioorg. Med. Chem. 2009, 17, 2371–2380. [CrossRef] [PubMed]
23. Ji, H.; Delker, S.L.; Li, H.; Martasek, P.; Roman, L.J.; Poulos, T.L.; Silverman, R.B. Exploration of the active
site of neuronal nitric oxide synthase by the design and synthesis of pyrrolidinomethyl 2-aminopyridine
derivatives. J. Med. Chem. 2010, 53, 7804–7824. [CrossRef] [PubMed]
24. Xue, F.; Fang, J.; Lewis, W.W.; Martasek, P.; Roman, L.J.; Silverman, R.B. Potent and selective neuronal nitric
oxide synthase inhibitors with improved cellular permeability. Bioorg. Med. Chem. Lett. 2010, 20, 554–557.
[CrossRef] [PubMed]

Molecules 2016, 21, 1160
21 of 21
25. Jing, Q.; Li, H.; Fang, J.; Roman, L.J.; Martasek, P.; Poulos, T.L.; Silverman, R.B. In search of potent and
selective inhibitors of neuronal nitric oxide synthase with more simple structures. Bioorg. Med. Chem. 2013,
21, 5323–5331. [CrossRef] [PubMed]
26. Xue, F.; Gu, W.; Silverman, R.B. Concise route to the chiral pyrrolidine core of selective inhibitors of neuronal
nitric oxide. Org. Lett. 2009, 11, 5194–5197. [CrossRef] [PubMed]
27. Satyamurthy, N.; Barrio, J.R. No-Carrier-Added Nucleophilic [F-18]Fluorination of Aromatic Compounds.
Patent PTC/US2010/001012, 17 May 2010.
28. Cardinale, J.; Ermert, J.; Humpert, S.; Coenen, H.H. Iodonium ylides for one-step, no-carrier-added
radiofluorination of electron rich arenes, exemplified with 4-(([18F]fluorophenoxy)phenylmethyl)-piperidine
NET and SERT ligands. RSC Adv. 2014, 4, 17293. [CrossRef]
29. Cardinale, J.; Ermert, J. Simplified synthesis of aryliodonium ylides by a one-pot procedure. Tetrahedron Lett.
2013, 54, 2067–2069. [CrossRef]
30. Tredwell, M.; Preshlock, S.M.; Taylor, N.J.; Gruber, S.; Huiban, M.; Passchier, J.; Mercier, J.; Genicot, C.;
Gouverneur, V. A general copper-mediated nucleophilic 18F-fluorination of arenes. Angew. Chem. Int.
Ed. Engl. 2014, 53, 7751–7755. [CrossRef] [PubMed]
31. Zlatopolskiy, B.D.; Zischler, J.; Krapf, P.; Zarrad, F.; Urusova, E.A.; Kordys, E.; Endepols, H.; Neumaier, B.
Copper-mediated aromatic radiofluorination revisited: Efficient production of PET tracers on a preparative
scale. Chemistry 2015, 21, 5972–5979. [CrossRef] [PubMed]
32. Lam, P.Y.S.; Clark, C.G.; Saubern, S.; Adams, J.; Averill, K.M.; Chan, D.M.T.; Combs, A. Copper promoted
aryl/saturated heterocyclic C-N bond cross-coupling with arylboronic acid and arylstannane. Synlett 2000
5, 674–676. [CrossRef]
,
33. Kügler, F.; Ermert, J.; Kaufholz, P.; Coenen, H.H. 4-[18F]Fluorophenylpiperazines by Improved
Hartwig-Buchwald N-arylation of 4-[18F]fluoroiodobenzene, Formed via Hypervalent 3-Iodane Precursors:
λ
Application to build-up of the dopamine D4 ligand [18F]FAUC 316. Molecules 2015, 20, 470–486. [CrossRef]
[PubMed]
34. Qaim, S.M.; Clark, J.C.; Crouzel, C.; Guillaume, M.; Helmeke, H.J.; Nebeling, B.; Pike, V.W.; Stöcklin, G. PET
radionuclide production. In Radiopharmaceuticals for Positron Emission Tomography; Stöcklin, G., Pike, V.W.,
Eds.; Kluwer Academic Publishers: Dordrecht, The Netherlands, 1993; p. 9.
35. Wyffels, L.; Muccioli, G.G.; De Bruyne, S.; Moerman, L.; Sambre, J.; Lambert, D.M.; De Vos, F.
Synthesis, in vitro and in vivo evaluation, and radiolabeling of aryl anandamide analogues as candidate
radioligands for in vivo imaging of fatty acid amide hydrolase in the brain. J. Med. Chem. 2009, 52, 4613–4622.
[CrossRef] [PubMed]
36. Landge, K.P.; Jang, K.S.; Lee, S.Y.; Chi, D.Y. Approach to the synthesis of indoline derivatives from
diaryliodonium salts. J. Org. Chem. 2012, 77, 5705–5713. [CrossRef] [PubMed]
37. Fan, X.X.; Xu, Y.; Liu, D.; Costanzo, M.J. Polycyclic Compounds and Methods of Making and Using the Same.
Patent PTC/US2013/073882, 19 June 2014.
38. Haynes, J.S.; Rettig, S.J.; Sams, J.R.; Trotter, J.; Thompson, R.C. Pyrazine and pyridine complexes of
copper(II) trifluoromethanesulfonate. Crystal-structure of Tetrakis(Pyridine)bis(Trifluoromethanesulfonato-
O)Copper(II) and Magnetic Exchange in (Pyrazine)bis(Trifluoromethanesulfonato-O)Copper(II). Inorg. Chem.
1988, 27, 1237–1241. [CrossRef]
39. Rotstein, B.H.; Stephenson, N.A.; Vasdev, N.; Liang, S.H. Spirocyclic hypervalent iodine(III)-mediated
radiofluorination of non-activated and hindered aromatics. Nat. Commun. 2014, 5, 4365. [CrossRef]
[PubMed]
40. Coenen, H.H.; Ermert, J. Direct nucleophilic 18F-fluorination of electron rich arenes: Present limits of
no-carrier-added reactions. Curr. Radiopharm. 2010, 3, 163–173. [CrossRef]
41. Rotstein, B.H.; Wang, L.; Liu, R.Y.; Patteson, J.; Kwan, E.E.; Vasdev, N.; Liang, S.H. Mechanistic studies and
radiofluorination of structurally diverse pharmaceuticals with spirocyclic iodonium(III) ylides. Chem. Sci.
2016, 7, 4407–4417. [CrossRef] [PubMed]
Sample Availability: Not available.
©
2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).